A novel model of liver cancer stem cells developed from induced pluripotent stem cells

Afify, Said M.; Calle, Anna Sanchez; Hassan, Ghmkin; Kumon, Kazuki; Nawara, Hend M.; Zahra, Maram H.; Mansour, Hager; Khayrani, Apriliana Cahya; Alam, M.J.; Du, Jie; Seno, Akimasa; Iwasaki, Yoshiaki; Seno, Masaharu

doi:10.1038/s41416-020-0792-z

Cited by 59 publications

(32 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, our group demonstrated that CSCs can be developed from iPSCs in the presence of CM prepared from various cancer cell lines [10][11][12]14]. Since our goal in this study was to reveal the synergistic action of PTX and Sor at low doses for growth inhibition of CSCs, we used our model of CSCs developed from iPSCs [12,14] to assess the effect of the combination at low concentration. The effect of the combination was evaluated on self-renewal, clonogenic, differentiation potential of CSCs, as well as proliferation.…”

Section: Discussionmentioning

confidence: 99%

“…Cancer stem cells, miPS-BT549cmP cells [12] and miPS-Huh7cmP cells [14], were obtained by the conversion of miPSCs (iPS-MEF-Ng-20D-17, Lot No. 012, Riken Cell Bank, Tokyo, Japan), in which the puromycin (puro) resistant gene and green fluorescent protein (GFP) gene were cloned under the control of the Nanog promoter, in the presence of CM from human breast cancer cell line BT549 cells (ATCC HTB-122) and the human liver cancer cell line Huh7 cell line (Riken Cell Bank).…”

Section: Cell Culturementioning

confidence: 99%

“…Our group recently demonstrated that CSCs could be developed from induced pluripotent stem cells (iPSCs) in the presence of conditioned medium (CM) from cancer cell lines [10][11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

“…In this study, we evaluated the combination of two different conventional drugs, paclitaxel (PTX) and sorafenib (Sor), employing the CSCs developed from mouse iPSCs in the presence of the CM from human breast cancer cell line BT549 and liver cancer cell line Huh7 [12,14]. PTX is a typical anti-cancer agent extracted from the bark of the Pacific Yew tree, Taxus brevifolia, stabilizing tubulin polymers and preventing disassembly of microtubules.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Paclitaxel and Sorafenib: The Effective Combination of Suppressing the Self-Renewal of Cancer Stem Cells

Nawara

Afify

Hassan

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

“Combination therapy”, which is a treatment modality combining two or more therapeutic agents, is considered a cornerstone of cancer therapy. The combination of anticancer drugs, of which functions are different from the other, enhances the efficiency compared to the monotherapy because it targets cancer cells in a synergistic or an additive manner. In this study, the combination of paclitaxel and sorafenib in low concentration was evaluated to target cancer stem cells, miPS-BT549cmP and miPS-Huh7cmP cells, developed from mouse induced pluripotent stem cells. The synergistic effect of paclitaxel and sorafenib on cancer stem cells was assessed by the inhibition of proliferation, self-renewal, colony formation, and differentiation. While the IC50 values of paclitaxel and sorafenib were approximately ranging between 250 and 300 nM and between 6.5 and 8 µM, respectively, IC50 of paclitaxel reduced to 20 and 25 nM, which was not toxic in a single dose, in the presence of 1 µM sorafenib, which was not toxic to the cells. Then, the synergistic effect was further assessed for the potential of self-renewal of cancer stem cells by sphere formation ability. As a result, 1 µM of sorafenib significantly enhanced the effect of paclitaxel to suppress the number of spheres. Simultaneously, paclitaxel ranging in 1 to 4 nM significantly suppressed not only the colony formation but also the tube formation of the cancer stem cells in the presence of 1 µM sorafenib. These results suggest the combination therapy of paclitaxel and sorafenib in low doses should be an attractive approach to target cancer stem cells with fewer side effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Cell Culturementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Paclitaxel and Sorafenib: The Effective Combination of Suppressing the Self-Renewal of Cancer Stem Cells

Nawara

Afify

Hassan

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…Currently, we have successfully been developing models for liver, lung, pancreas, and breast CSCs. Our models have given some insights on the differentiation potential of CSCs and their interactions with cancer-associated cells including fibroblasts and immune cells [43,[164][165][166]. We believe that these CSC models with other recent models deriving from normal cells could provide unique tools for future applications of biomaterial 3D scaffold mimicking tumor microenvironment.…”

Section: Conclusion and Future Perspectivementioning

confidence: 99%

Cancer Stem Cell Microenvironment Models with Biomaterial Scaffolds In Vitro

et al. 2020

Self Cite

View full text Add to dashboard Cite

Defined by its potential for self-renewal, differentiation and tumorigenicity, cancer stem cells (CSCs) are considered responsible for drug resistance and relapse. To understand the behavior of CSC, the effects of the microenvironment in each tissue are a matter of great concerns for scientists in cancer biology. However, there are many complicated obstacles in the mimicking the microenvironment of CSCs even with current advanced technology. In this context, novel biomaterials have widely been assessed as in vitro platforms for their ability to mimic cancer microenvironment. These efforts should be successful to identify and characterize various CSCs specific in each type of cancer. Therefore, extracellular matrix scaffolds made of biomaterial will modulate the interactions and facilitate the investigation of CSC associated with biological phenomena simplifying the complexity of the microenvironment. In this review, we summarize latest advances in biomaterial scaffolds, which are exploited to mimic CSC microenvironment, and their chemical and biological requirements with discussion. The discussion includes the possible effects on both cells in tumors and microenvironment to propose what the critical factors are in controlling the CSC microenvironment focusing the future investigation. Our insights on their availability in drug screening will also follow the discussion.

show abstract

Breaking Down the Arsenal: Recent Progress in the Nanotherapeutic Strategies for Hepatocellular Carcinoma Treatment

Roy,

Harish,

Mohd

et al. 2024

Advanced Therapeutics

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a progressed form of advanced liver cancer and is one of the major causes of global cancer burden. The primary causes for high HCC mortality is the delayed diagnosis of the diseaseas early stage HCC is typically asymptomatic and patients frequently overlook the warning signs. Currently, the most efficacious single‐drug therapy approved by the food and drug administration (FDA) for HCC is Sorafenib and Nivolumab as a second‐line therapy for late stage HCC. Nowadays nanotechnology is used to deliver either a diagnostic tool for biomolecular imaging ortherapeutic agent. Gene therapy based on clustered regularly interspaced short palindromic repeats (CRISPR)‐CRISPR associated protein 9 (CRISPR‐Cas9) are currently studied to find a potential curative option for HCC. Natural products from plants are being extensively extracted and isolated as they may offer a promising alternative in order to control and treat HCC. They exhibit anti‐HCC effects by stimulating the immune system and by hindering various growth pathways involved in cancer development and progression. In this review article, an overview is provided on the current global incidence, ongoing systemic treatment strategies, and recent advances in nanomedicine for the management of HCC and also ongoing efforts to overcome these challenges.

show abstract

A novel model of liver cancer stem cells developed from induced pluripotent stem cells

Cited by 59 publications

References 39 publications

Paclitaxel and Sorafenib: The Effective Combination of Suppressing the Self-Renewal of Cancer Stem Cells

Paclitaxel and Sorafenib: The Effective Combination of Suppressing the Self-Renewal of Cancer Stem Cells

Cancer Stem Cell Microenvironment Models with Biomaterial Scaffolds In Vitro

Breaking Down the Arsenal: Recent Progress in the Nanotherapeutic Strategies for Hepatocellular Carcinoma Treatment

Contact Info

Product

Resources

About